HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
OPRX
OptimizeRx Corporation
OPRX's fundamentals are strong: its operating margin went from −3.7% to 11% and it turned 19% of its revenue into free cash flow, though revenue fell 5.8%. At 37x earnings, it's trading less than half its usual 600x. Analysts expect strong earnings growth.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
OPRX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Strong | |
| Strong |
OPRX's profitability, cash flow and balance sheet are currently healthy, but its revenue is under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
OPRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.2x | $8.87 | — |
| Cheap | 20x | $4.88 | -45% |
| Current | 37x | $8.87 | — |
| Fair | 592x | $142 | +1503% |
| Expensive | 1,627x | $391 | +4303% |
Historical ranges are pointers, not guarantees.
OPRX's PE is in its fair range at 37x. If earnings grow as analysts expect, today's price would be 9.2x next year's earnings, in its cheap range.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
OPRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OPRX has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
OPRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.97 | +304% |
| Q2 2026 | $0.24 | +$0.78 |
| Q1 2026 | $0.36 | +$1.20 |
| Q4 2025 | $0.27 | +$1.37 |
| Q3 2025 | $0.00 | +$1.35 |
| Q2 2025 | -$0.54 | +$0.48 |
| Q1 2025 | -$0.84 | +$0.20 |
| Q4 2024 | -$1.10 | -$0.07 |
| Q3 2024 | -$1.35 | -$0.54 |
OPRX has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over OPRX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
OPRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $20.5M | -30% |
| Q1 2026 | $19.8M | -9.5% |
| Q4 2025 | $32.2M | -0.2% |
| Q3 2025 | $26.1M | +22% |
| Q2 2025 | $29.2M | +2307% |
| Q1 2025 | $21.9M | +1168770% |
| Q4 2024 | $32.3M | +14% |
| Q3 2024 | $21.3M | +30% |
OPRX's revenue has slid since its 2024 peak: $21M last quarter, down 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -0.4% | -11 points |
| Q1 2026 | 2% | +12 points |
| Q4 2025 | 27% | +15 points |
| Q3 2025 | 7.9% | +48 points |
| Q2 2025 | 11% | +320 points |
| Q1 2025 | -9.6% | +268061 points |
| Q4 2024 | 11% | +50 points |
| Q3 2024 | -40% | -18 points |
OPRX has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
OPRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $8.6M | +88% |
| Q1 2026 | -$488K | -113% |
| Q4 2025 | $7.1M | +3810% |
| Q3 2025 | $3.2M | +80% |
| Q2 2025 | $4.6M | +518% |
| Q1 2025 | $3.8M | +84% |
| Q4 2024 | $181K | +$6.4M |
| Q3 2024 | $1.8M | +23% |
OPRX generated $18M in free cash flow over the past year, up 77% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over OPRX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
OPRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +24K shares |
| 1 year | -1.2% | -230K shares |
| 3 years | +11% | +1.8M shares |
| 5 years | +3.8% | +681K shares |
| Available history | +33% | +4.6M shares |
OPRX has 19M diluted shares, down 1.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q2 2023 | $7.5M |
| Q4 2022 | $7.5M |
| Q3 2022 | $12.2M |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over OPRX on leverage, with a lower net debt burden relative to earnings.
OPRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 23.5x | High |
OPRX has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
OPRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.0 | Neutral |
| Stochastic | 77.6 | Neutral |
OPRX's weekly RSI is 57 (neutral) and its Stochastic is 78 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
OPRX PE vs Healthcare Sector
| Metric | OPRX | Sector median | Relative |
|---|---|---|---|
| PE | 37x | 26x | 43% above |
| PE % | 45 | 29 | 16 pts above |
OPRX is trading at 37x earnings, a 43% premium to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
OPRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.69 | 2.1% above |
| 20 week MA | $7.75 | 14% above |
| 50 week MA | $8.11 | 9.4% above |
| 100 week MA | $10.1 | 12% below |
| 200 week MA | $10.7 | 17% below |
OPRX has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
OPRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.1 | $31.6 | +214% |
| 2021 | $31.6 | $60.5 | +92% |
| 2022 | $60.5 | $16.7 | -72% |
| 2023 | $16.7 | $14.3 | -14% |
| 2024 | $14.3 | $5.09 | -64% |
| 2025 | $5.09 | $12.5 | +145% |
| 2026 YTD | $12.5 | $8.87 | -29% |
OPRX has the edge over HIMS on returns for 2026, with the stronger performance.